modernretina

Q&A: Evolving approaches to geographic atrophy management

David S. Boyer, MD, outlines changes in GA evaluation, the role of complement inhibition, monitoring for neovascular conversion, and emerging therapies. In this Q&A conversation, the Eye Care Network ...
modernretina

A medical fellow finds some magic at the AAO Annual Meeting

The value of attending industry meetings at the beginning of a career in ophthalmology. Attending the American Academy of Ophthalmology (AAO) Annual Meeting for the first time can feel overwhelming.
modernretina

The gene therapy shift: A closer look at the science powering next-generation retinal treatments

Gene therapy revolutionizes retinal disease treatment, offering long-lasting solutions and reducing the need for frequent injections in patients with nAMD. Over the past decade, intravitreal ...
modernretina

AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives

AAO 2025 highlights groundbreaking advancements in retinal disease treatments, showcasing senolytics, optogenetics, and personalized therapies for improved patient outcomes. At AAO 2025, the ...
modernretina

Beacon Therapeutics announces positive topline data from DAWN and SKYLINE trials

Beacon Therapeutics shares promising phase 2 trial results for laru-zova, a gene therapy showing potential in treating X-linked retinitis pigmentosa. Beacon Therapeutics recently revealed topline data ...
modernretina

Ursula Schmidt-Erfurth, MD, discusses her keynote EURETINA Lecture

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration. At this year's meeting of the European Society ...
modernretina

Ashvattha announces positive topline data for MGB for the treatment of DME and nAMD

The 40-week phase 2 clinical trial was a multicenter, chronic dosing trial for the evaluation of the safety and efficacy of subcutaneous MGB, “an investigational VEGF receptor tyrosine kinase ...
modernretina

Q&A: David Eichenbaum, MD, on the ARCHER-2 study for dry AMD and GA

David A. Eichenbaum, MD, FASRS, a partner and director of research at Retina Vitreous Associates of Florida and collaborative volunteer Associate Professor at the Morsani College of Medicine at the ...
modernretina

First FDA-approved MacTel treatment performed

Neurotech Pharmaceuticals performs the first ENCELTO procedure. Neurotech Pharmaceuticals recently announced the first commercial manufacturing, shipment, and surgical procedure of the first and only ...
modernretina

ASRS 2025: Underfunding of Good Days program affect on patients and practices

Lai spoke with Modern Retina about the study of PER-001, a novel therapeutic targeting the endothelin-1 receptor. Michael Lai, MD, PhD, presented at the 2025 annual scientific meeting of the American ...
modernretina

Q&A: A look at suprachoroidal avoralstat with Dilsher S. Dhoot at ASRS 2025

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025. The American Society of Retina Specialists (ASRS) is holding their 2025 ...
modernretina

EyePoint completes enrollment of LUGANO and LUCIA trials

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD. EyePoint Pharmaceuticals recently announced the completion of ...